In addition, it has been reported that ERK MAPK pathway is not involved in MCDD-induced NASH, however its activation is reported to decrease DGAT2 expression; ERK activation is probably required for the treatment of the disease [42,44]. The gene discussed is DGAT2; the disease is metabolic dysfunction-associated steatohepatitis.